The estimated Net Worth of Carl B Feldbaum is at least $3.43 Milión dollars as of 9 February 2023. Mr. Feldbaum owns over 40,000 units of Exelixis Inc stock worth over $1,563,208 and over the last 18 years he sold EXEL stock worth over $1,417,678. In addition, he makes $446,780 as Independent Director at Exelixis Inc.
Sign up
Mr. Feldbaum EXEL stock SEC Form 4 insiders trading
Carl has made over 12 trades of the Exelixis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of EXEL stock worth $252,000 on 9 February 2023.
The largest trade he's ever made was exercising 50,500 units of Exelixis Inc stock on 14 February 2019 worth over $251,490. On average, Carl trades about 9,803 units every 66 days since 2007. As of 9 February 2023 he still owns at least 58,701 units of Exelixis Inc stock.
You can see the complete history of Mr. Feldbaum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carl Feldbaum biography
Carl B. Feldbaum Esq., J.D. serves as Independent Director of the Company. Carl B. Feldbaum, Esq., has been a director since February 2007. Mr. Feldbaum serves as a member emeritus of the board of directors of BIO Ventures for Global Health, a non-profit organization, and is president emeritus of the Biotechnology Innovation Organization (BIO), which is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Mr. Feldbaum served as president of BIO from 1993 until his retirement in 2005. Prior to joining BIO, Mr. Feldbaum was chief of staff to Senator Arlen Specter of Pennsylvania. He also was president and founder of Palomar Corporation, a national security “think tank” in Washington, D.C. Before founding Palomar Corporation, Mr. Feldbaum was Assistant to the Secretary of Energy and served as the Inspector General for defense intelligence in the U.S. Department of Defense. Mr. Feldbaum served as a member of the board of directors of the following publicly held companies: Actelion, Ltd, a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs (acquired by Johnson & Johnson in 2017), from 2005 to 2015; Trovagene, Inc., a precision medicine biotechnology company focused on the development of oncology therapeutics for improved cancer care, from 2014 to 2015; and Connetics Corporation, a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market, from 2005 until its acquisition by Stiefel Laboratories, Inc. in 2006. Mr. Feldbaum holds an A.B. in Biology from Princeton University and a J.D. from the University of Pennsylvania Law School.
What is the salary of Carl Feldbaum?
As the Independent Director of Exelixis Inc, the total compensation of Carl Feldbaum at Exelixis Inc is $446,780. There are 17 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
How old is Carl Feldbaum?
Carl Feldbaum is 76, he's been the Independent Director of Exelixis Inc since 2007. There are 1 older and 20 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
What's Carl Feldbaum's mailing address?
Carl's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Insiders trading at Exelixis Inc
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey a Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
What does Exelixis Inc do?
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
What does Exelixis Inc's logo look like?
Complete history of Mr. Feldbaum stock trades at Exelixis Inc
Exelixis Inc executives and stock owners
Exelixis Inc executives and other stock owners filed with the SEC include:
-
Dr. Michael M. Morrissey,
CEO, Pres & Director -
Michael Morrissey,
President, Chief Executive Officer, Director -
Gisela Schwab,
President - Product Development and Medical Affairs, Chief Medical Officer -
Christopher J. Senner,
Exec. VP & CFO -
Christopher Senner,
Chief Financial Officer, Executive Vice President -
Jeffrey J. Hessekiel,
Exec. VP, Gen. Counsel & Sec. -
Jeffrey Hessekiel,
Executive Vice President, General Counsel -
Patrick J. Haley M.B.A., MBA,
Exec. VP of Commercial -
Peter Lamb,
Executive Vice President - Scientific Strategy, Chief Scientific Officer -
Stelios Papadopoulos,
Independent Chairman of the Board, Co-Founder -
Charles Cohen,
Independent Director -
Jack Wyszomierski,
Independent Director -
George Poste,
Independent Director -
Vincent Marchesi,
Independent Director -
Julie Smith,
Independent Director -
Alan Garber,
Independent Director -
Maria Freire,
Independent Director -
Carl Feldbaum,
Independent Director -
Lance Willsey,
Independent Director -
Dr. Stelios Papadopoulos Ph.D.,
Co-Founder & Independent Chairman -
Patrick Haley,
Executive Vice President - Commercial -
Laura Dillard,
Exec. VP of HR -
Gregg Bernier,
VP of Marketing -
Susan T. Hubbard,
Exec. VP of Public Affairs & Investor Relations -
Dr. Peter Lamb,
Exec. VP of Scientific Strategy & Chief Scientific Officer -
Dr. Dana T. Aftab,
Exec. VP of Bus. Operations -
George A Scangos,
Director -
Dana Aftab,
CSO/EVP Disc & Trans Research -
Mary C Beckerle,
Director -
David Edward Caligan Partne...,
-
Sue Gail Eckhardt,
Director -
Bob Oliver,
Director -
Tomas J. Heyman,
Director -
Jacqueline Wright,
Director -
Pamela A Simonton,
VP, Corp Tech Development -
Frank Karbe,
Senior VP & CFO -
Deborah Burke,
SVP & Chief Financial Officer -
Jeffrey Latts,
Sr VP, Chief Medical Officer -
Peter Stalder,
Director -
Jason S Fisherman,
Director -
Kristine M Ball,
Controller & Interim CFO -
Frank Mccormick,
Director -
Steven P James,
Sr VP, Commercial Ops -
Jane M Green,
VP, Corp Communications -
Glen Y Sato,
CFO Sec and General Counsel -
Jean Francois Formela,
Director -
Lupe M Rivera,
VP, HUMAN RESOURCES -
Frances K Heller,
EVP, Business Development -
Ian D Malcolm,
VP, STRATEGIC MARKETING -
Christoph Pereira,
VP, Legal Affairs & Secretary -
J. Scott Garland,
EVP & Chief Commerical Officer -
Gregory Plowman,
Sr VP, Research -
Geoffrey M Duyk,
Pres R&D & Chief Sc Off -
Vicki L Goodman,
EVP, Prod Dev & Med Aff &CMO -
Amy C. Peterson,
EVP Prod Dev & Med Aff & CMO